Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
22.62 (USD) • At close November 13, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Omzet
| 270.259 | 220.18 | 38.544 | 0 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| 56.524 | 46.966 | 9.1 | 3.805 | 3.279 | 0.286 | 0.028 | 0.022 |
| Brutowinst
| 213.735 | 173.214 | 29.444 | -3.805 | -3.279 | -0.286 | -0.028 | -0.022 |
| Brutowinstmarge
| 0.791 | 0.787 | 0.764 | 0 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 76.097 | 65.49 | 99.297 | 112.042 | 135.001 | 86.597 | 56.357 | 17.439 |
| Algemene en administratieve kosten
| 0 | 0 | 0 | 0 | 34.962 | 21.563 | 9.043 | 6.563 |
| Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 129.427 | 97.951 | 85.948 | 45.321 | 34.962 | 21.563 | 9.043 | 6.563 |
| Overige kosten
| 33.407 | 1.253 | 0.835 | 0 | 0 | 0 | 0 | 0 |
| Bedrijfskosten
| 262.048 | 163.441 | 186.08 | 157.363 | 169.963 | 108.16 | 65.4 | 24.002 |
| Bedrijfsresultaat
| -25.196 | 7.371 | -156.636 | -157.363 | -169.963 | -108.16 | -65.4 | -24.002 |
| Bedrijfsresultaat ratio
| -0.093 | 0.033 | -4.064 | 0 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| 8.544 | 1.253 | 0.097 | 1.134 | 6.049 | 4.719 | 0.529 | 0.065 |
| Inkomen voor belasting
| -16.652 | 11.026 | -156.539 | -156.229 | -163.914 | -103.441 | -64.871 | -23.937 |
| Inkomen voor belasting ratio
| -0.062 | 0.05 | -4.061 | 0 | 0 | 0 | 0 | 0 |
| Belastingkosten
| -30.736 | -172.337 | 1.385 | 5.152 | -2.047 | -0.214 | 0.002 | 0.036 |
| Nettowinst
| 14.084 | 183.363 | -157.924 | -161.381 | -161.867 | -103.227 | -64.873 | -23.973 |
| Nettowinstmarge
| 0.052 | 0.833 | -4.097 | 0 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| 0.2 | 2.64 | -2.3 | -2.61 | -2.99 | -3.49 | -2 | -0.74 |
| Verwaterde WPA
| 0.2 | 2.6 | -2.3 | -2.61 | -2.99 | -3.49 | -2 | -0.74 |
| EBITDA
| -22.855 | 9.773 | -154.281 | -152.424 | -167.895 | -107.874 | -65.372 | -23.98 |
| EBITDA ratio
| -0.085 | 0.044 | -4.064 | 0 | 0 | 0 | 0 | 0 |